NEW YORK (360Dx) – NeoGenomics today reported a 4 percent year-over-year increase in its total third quarter revenues, as clinical testing revenues grew less than 1 percent. 

For the three months ending Sept. 30, total revenues rose to $63.1 million from $60.8 million in the year-ago period, but fell short of the consensus Wall Street estimate of $63.9 million. 

Clinical testing revenues inched up to $56.2 million from $55.7 million in Q3 2016, and pharma services revenues rose 38 percent to $6.9 million from $5.0 million a year ago. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.